PREVALENCE AND KINETICS OF ANTI-INFLIXIMAB ANTIBODIES DURING INFLIXIMAB THERAPY
- Sophie DESPLAT-JEGO, France
Abstract
Background and Aims
Background and aims: Infliximab (IFX) is a monoclonal therapeutic anti-TNF antibody with proven efficiency in chronic inflammatory diseases. However, a significant number of patients have no primary response or lose response becoming secondary non-responders. The production of anti-drug antibodies (ADAb) increasing IFX serum clearance has been identified as a possible explanation. However the prevalence and kinetics of ADAb are not well described. Our aim was to evaluate the occurrence of ADAb in a large cohort of infliximab-treated patients.
Methods
Method: A cohort of 817 serum samples sent to our lab between 2016 and 2019 for concomitant evaluation of infliximabemia and ADAb (Lisa-Tracker, Théradiag, France) was retrospectively studied.
Results
Results: In our cohort, 91 out of 817 samples (11.13 %) were found positive for ADAb. Among them, 53 samples (58.2 %) displayed a concentration of ADAb superior to 200 µg/ml. The 91 positive samples corresponded to 71 patients and we had a longitudinal follow-up for 14 patients. Among these later, 11 patients had a stable level of ADAb during several months (>200 µg/ml for 9 patients) while we observed a modulation of ADAb levels in the 3 other ones (down-modulation in 2 cases and up-modulation in one case).
Conclusions
Conclusions: We showed here that the prevalence of ADAb during infliximab therapy is quite elevated (11, 13 %). Moreover, in our study, the ADAb levels are mainly high and seem stable. However in a minority of patients we could observe a modulation of ADAb levels during the infliximab therapy.